Abstract
Galectin-3 plays a role in atherosclerotic diseases, and the effect of adiponectin that protects from atherosclerotic diseases on monocytic galectin-3 was analysed. Adiponectin reduced galectin-3 mRNA, its cellular and soluble form, and this effect was impaired in T2D cells. Cellular galectin-3 was higher in monocytes of overweight than normal-weight donors and was highest in T2D cells. Cellular galectin-3 positively correlated with the BMI of the donors and negatively with soluble monocyte galectin-3. Circulating levels of total adiponectin did not correlate with cellular or soluble galectin-3 indicating that additional factors contribute to higher cellular monocytic galectin-3 in obesity and T2D.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adiponectin / pharmacology*
-
Adult
-
Aged
-
Aged, 80 and over
-
Aminoimidazole Carboxamide / analogs & derivatives
-
Aminoimidazole Carboxamide / pharmacology
-
Body Mass Index
-
Cells, Cultured
-
Cholesterol / metabolism
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / metabolism*
-
Dose-Response Relationship, Drug
-
Enzyme-Linked Immunosorbent Assay
-
Galectin 3 / chemistry
-
Galectin 3 / genetics
-
Galectin 3 / metabolism*
-
Humans
-
Immunoblotting
-
Male
-
Metformin / pharmacology
-
Middle Aged
-
Monocytes / cytology
-
Monocytes / drug effects*
-
Monocytes / metabolism
-
Oleic Acid / pharmacology
-
Palmitic Acid / pharmacology
-
Pyrazoles / pharmacology
-
Pyrimidines / pharmacology
-
Reverse Transcriptase Polymerase Chain Reaction
-
Ribonucleotides / pharmacology
-
Solubility
-
Time Factors
Substances
-
Adiponectin
-
Galectin 3
-
Pyrazoles
-
Pyrimidines
-
Ribonucleotides
-
dorsomorphin
-
Oleic Acid
-
Palmitic Acid
-
Aminoimidazole Carboxamide
-
Metformin
-
Cholesterol
-
AICA ribonucleotide